Sito Epatite C
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Portale Epatite e malattie del fegato
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–98. (ION-1)

    2. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93. (ION-2)

    3. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88. (ION-3)

    4. Naggie S et al. Ledipasvir and sofosbuvir for 12 weeks in patients coinfected with HCv and HIV-1. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). 2015. (ION-4)

    5. Gane EJ et al. High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection AASLD, 2014, Poster #LB-11 (ELECTRON-2)

    6. Gane EJ et al. Ledipasvir/Sofosbuvir ± Ribavirin in Difficult-to-Treat HCV Populations. EASL, 2014, Oral #6 (ELECTRON-2)

    7. Kapoor R et al. Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 weeks: Results of the SYNERGY Trial. AASLD, 2014, Oral #240

    8. Charlton M et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015 (epub ahead of print) (SOLAR-1)

    9. Manns M et al. Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial, EASL, 2015, Oral presentation GO2;

    10. Osinusi et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31;313(12):1232-9

    11. Harvoni: Riassunto delle Caratteristiche del Prodotto


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!